Clinical trials for Huntington’s Disease often vary. If you can’t find a trial you’re looking for or one that interests you, please bookmark this page and check back often for updates
Research Coordinator Contact Information
Christine O'Neill: firstname.lastname@example.org 336-716-8611
Wake Forest Baptist Medical Center, Winston Salem, NC
McKenzie Luxmore: email@example.com 919-684-0865
Duke Movement Disorder Center, Durham, NC
Enrollment is open.
Study Sponsor: Huntington Study Group, Center for Huntington’s Disease International
Clinical Sites in NC: Duke, Wake Forest
Enroll-HD is a worldwide observational study for Huntington’s disease families. It collects information about how disease symptoms first appear and change over time. It is open to people who have the HD gene, at-risk individuals, and spouses or caregivers. Enroll-HD is a prospective observational study, meaning it tracks people over time, rather than asking them to recall how their symptoms have changed. Enroll-HD is also an important platform for helping to launch important clinical trials. The goal of this study is that it will make other HD research easier to conduct, thereby speeding up the process of developing new drugs and other treatments that really work.
For more information see the CHDI webpage for Enroll HD and see the Enroll HD brochure.
WAVE – PRECISION HD
Estimated to begin enrollment in early Summer 2018
Study Sponsor: Wave Life Sciences
Phase: Phase Ib/2a, Safety and Tolerability Study
Clinical Sites in NC: Wake Forest
Website: http:// www.wavelifesciences.com
The purpose of the study is to find out if the investigational drug WVE-120101 is safe and if it will reduce the production of the mutant huntingtin protein (mHTT). The intent is that if in reducing or removing the mutant protein (mHTT), there will be an improvement in the symptoms of HD. The study will measure the safety and tolerability of the new drug and assess the effect of the drug on signs and symptoms of HD.
Study Sponsor: Center for Huntington's Disease International
Clinical Sites: Wake Forest
HD Clariity is a worldwide, multi-site initiative to collect cerebrospinal fluid (CSF) from HD persons and controls (non-HD persons). The CSF is needed to facilitate therapeutic development for Huntington's disease. CSF is an accessible body fluid that may: 1) help our understanding of HD progression; 2) help identify potential targets for intervention, and 3) help identify potential biomarkers. A biomarker is a measurable indicator of the severity or presence of a particular disease state. Biomarkers are needed to advance and accelerate upcoming clinical trials. This study is open to all people who have the HD gene, as well as to spouses or caregivers who may serve as control subjects. You must be a participant in the Enroll-HD study to be considered for the HD Clarity study.
Study Sponsor: Vaccinex Pharmaceuticals
Phase: Phase II, Safety and Efficacy
Clinical Sites in NC: Duke, Wake Forest
The SIGNAL trial is designed to assess the safety, tolerability, and effectiveness of VX15, a novel monoclonal antibody in people with late prodromal or early manifest Huntington’s disease (HD). VX15 is a different class of drug than any other drug used in previous HD clinical trials. Monoclonal antibodies are more specific than most other drugs because they only bind to and neutralize their desired target.
Enrollment is closed. Study still in progress.
Study Sponsor: Teva Pharmaceuticals, HSG, EHDN
Phase: Phase II, Safety
Clinical Sites in NC: None
The purpose of the LEGATO-HD trial is to see what effect different doses of an investigational drug called laquinimod may have on people with Huntington’s disease (HD) after 12 months of administration. You may be eligible to participate in the study if you are between the ages of 18 and 55 and have HD.
Didn't find the clinical trial you were looking for?
A search tool to identify all clinical trials that match your profile and the closest trial sites, and updates you when new studies open that match your profile.
Request a Contact or Search by Phone
Monday - Friday: 9:00 am - 6:00 pm ET